We serve Chemical Name:O4I1 CAS:175135-47-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:O4I1
CAS.NO:175135-47-4
Synonyms:2-[4-[(4-Methoxyphenyl)methoxy]phenyl]-acetonitrile;4-(4-methoxybenzyloxy)benzylnitrile;Benzeneacetonitrile, 4-[(4-methoxyphenyl)methoxy]-;{4-[(4-Methoxybenzyl)oxy]phenyl}acetonitrile;O4I1;2-(4-((4-Methoxybenzyl)oxy)phenyl)acetonitrile;2-(4-[(4-METHOXYBENZYL)OXY]PHENYL)ACETONITRILE;O4I-1
Molecular Formula:C16H15NO2
Molecular Weight:253.296
HS Code:2926909090
Physical and Chemical Properties:
Melting point:140ºC
Boiling point:424.5±30.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.570
PSA:42.25000
Exact Mass:253.110275
LogP:2.93
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-[4-[(4-Methoxyphenyl)methoxy]phenyl]-acetonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,O4I-1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,O4I-1 Use and application,Benzeneacetonitrile, 4-[(4-methoxyphenyl)methoxy]- technical grade,usp/ep/jp grade.
Related News: A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. O4I1 manufacturer The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. O4I1 supplier In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. O4I1 vendor Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. O4I1 factory The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.
